Fusidic Acid and Its Major Active Metabolite Penetration into Cerebrospinal Fluid for Assessing Treatment of Intracranial Infections.

Abstract

Fusidic acid (FA) had excellent antimicrobial effects due to its unique mechanism of action. Since 1962, FA has been widely used in the systemic and topical treatment of staphylococcal infections and exhibits a well-characterized potency against methicillin-susceptible Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, and methicillin-resistant coagulase-negative Staphylococci. In view of the spectrum of activity, no cross-resistance with other clinically used antibiotics, and potential penetration into brain tissue, FA was used to treat possible gra-positive bacteria in 3 patients with intracranial infections in the present report. FA and its active metabolite (3-keto FA) were measured in plasma and cerebrospinal fluid (CSF) to assess the treatment of FA, and the results indicated that 1,500 mg per day of FA was sufficient to achieve therapeutic concentrations in both plasma and CSF in intracranial infection patients, while the dosage did not experience unexpected regimen-related toxicity.

• Authors: Zhi Rao, Zhong-Fang He, Mao-Hua Zheng, Zi-Long Dang, Gang Yang, Yong-Hong Zhang, Ning Lu, Yu-Hui Wei
• Journal: Chemotherapy (Chemotherapy) Vol. 68 Issue 1 Pg. 48-54 ( 2023) ISSN: 1421-9794 [Electronic] Switzerland
• PMID: 35810737 (Publication Type: Case Reports)
• Copyright: © 2022 S. Karger AG, Basel.

Chemical References

• Fusidic Acid
• Anti-Bacterial Agents

Topics

• Humans
• Fusidic Acid (therapeutic use, pharmacology)
• Methicillin-Resistant Staphylococcus aureus
• Anti-Bacterial Agents (pharmacology, therapeutic use)
• Staphylococcal Infections (drug therapy, microbiology)
• Staphylococcus aureus
• Microbial Sensitivity Tests